GLP1R and type 2 diabetes mellitus: Is glucagon-like peptide-1 (GLP-1) receptor agonist (RA) use associated with a major adverse cardiovascular and cerebrovascular events (MACCE) in patients with monoclonal gammopathy of undetermined significance and type 2 diabetes without prior cardiovascular disease?